Colorectal cancer in patients with diabetes – epidemiology, pathophysiology and applications for clinical practice
Authors:
Alexandra Romanová 1; Jana Malinovská 1; Michala Lustigová 2,3; Jana Urbanová 4; Ludmila Brunerová 4; Veronika Vejtasová 5; Ankita Verma 1; Tung A. Duong 1; Jan Šťovíček 1; Jan Brož 1
Authors‘ workplace:
Interní klinika 2. LF UK a FN v Motole, Praha
1; Státní zdravotní ústav, Praha
2; Přírodovědecká fakulta UK, Praha
3; Interní klinika 3. LF UK a FNKV, Praha
4; Kardiologická klinika 2. LF UK a FN v Motole, Praha
5
Published in:
Vnitř Lék 2022; 68(2): 116-122
Category:
Review Articles
Overview
Diabetes mellitus (type 2 diabetes in particular) and colorectal carcinoma are relatively frequent diseases in our population. At the same time, these units share some common risk factors, for example obesity, lack of physical activity and hyperinsulinemia. Available data show patients with diabetes have increased risk of colorectal adenoma and carcinoma, increased risk of colorectal carcinoma at a lower age, as well as increased risk of relapse and increased mortality with colorectal cancer. The aim of this article is to point out the relationship between diabetes and colorectal carcinoma, with emphasis on the information important for clinical practice, particularly the screening of colorectal carcinoma and lifestyle recommendations for patients with diabetes. Therefore, we offer an overview of the important available publications which consider this topic.
Keywords:
Chemotherapy – treatment – primary prevention – DOAC – Trousseau syndrome – paraneoplastic thromboembolic disease – low-molecular-weight heparins
Sources
1. Zdravotnická ročenka České republiky 2018. Praha: ÚZIS ČR, 2019. ISSN ISSN 1210-9991.
2. Ogurtsova K, da Rocha Fernandes JD, Huang Y et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract.2017; 128,40-50.
3. Ling S, Brown K, Miksza J et al. Risk of cancer incidence and mortality associated with diabetes: A systematic review with trend analysis of 203 cohorts. Nutrition, Metabolism & Cardiovascular Diseases. 2021;31(1),14-22.
4. Coughlin S, Calle E, Teras L et al. Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults. American Journal of Epidemiology. 2004;159(12),1160-1167.
5. Hammer G, McPhee S et al. Pathophysiology of Disease: An Introduction to Clinical Medicine. Eighth Edition. China: The McGraw‑Hill Companies. 2019:553-581. ISBN 978-1-260-02950-4.
6. Urbanová J, Brunerová L, Brož J. Hidden MODY‑ Looking for a Needle in a Haystack. Front Endocrinol (Lausanne). 2018;Jul 2;9:355.
7. Zámečník J, ed. Patologie. Praha: LD Prager Publishing. 2019:461-526. ISBN 978-80-270-6457-1
Další literatura u autorů a na www.casopisvnitrnilekarstvi.cz
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
![Issue 2](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/5806d994e7db229d69c471b6a69ab7ac.jpg)
2022 Issue 2
Most read in this issue
- Oral semaglutide – Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
- The position of SGLT2 inhibitors in current medical practice – update 2022
- Prediabetes
- Anticoagulation in cancer patients; new recommendations based on randomized clinical trials